A Randomized Phase III Trial Of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles Of Docetaxel Plus Cyclophosphamide Or Four Cycles Of Doxorub
Posted Date: May 15, 2019
- Investigator: Elizabeth Shaughnessy
- Specialties: Breast Cancer, Cancer, Oncology
- Type of Study: Drug
This study will determine if adding a targed therapy to standard treatment with chemotherapy for early stage, HER2-low breast cancer, will prevent breast cancer from returning. Participation in this study will last for 10 years. Chemotherapy will take 4-6 months. About 3, 260 women will take part in
Criteria:
Eligible Patients Must Have Early Stage Breast Cancer That Has Been Removed By Surgery
Keywords:
B-47, Breast Cancer, Her2, High Risk, Node Negative
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu